UCB announced that the U.S. FDA has approved BRIVIACT® (brivaracetam) as adjunctive therapy (a therapy used together with primary treatment) in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. This approval is the culmination of more than eight years of clinical trials involving more than 2,400 adult patients with partial-onset seizures.  In January 2016, the European Commission granted the marketing authorization for BRIVIACT® as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients from 16 years of age with epilepsy. In the EU, BRIVIACT® is already available to patients in the UK and Germany.  Epilepsy is a chronic neurological disorder affecting approximately 65 million people worldwide and more than 2 million people in the U.S. It is the fourth most common neurological disorder in the U.S. Although epilepsy may be linked to factors such as health conditions, race and age, it can develop in anyone at any age. vApproximately one in 26 people will develop epilepsy in their lifetime.

 

Source:

http://www.ucb.com/presscenter/News/article/U-S-FDA-approves-UCB-s-new-epilepsy-treatment-BRIVIACT-for-patients-with-partial-onset-seizures